We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The Federal Trade Commission counted 29 pay-for-delay deals in fiscal year 2013 out of a total of 145 patent litigation settlements between brand and generic drugmakers — a slight decline from 2012, but in line with the two previous years. Read More
China has agreed to streamline its regulatory processes and cut red tape for imports of new drugs, a move that should benefit the U.S. pharmaceutical industry, the U.S. Commerce Department says. Read More
A leaked draft of the Trans Pacific Partnership trade agreement gives far too much intellectual property protection to brand drugmakers at the cost of generic competition, GPhA said Wednesday in a letter to the Obama administration. Read More
China’s FDA is threatening to severely punish companies that illegally manufacturer and sell codeine in the country, a warning the follows several revelations of the product was being sold in bulk quantities. Read More
Generic drug prices in Canada have fallen significantly in recent years, even while they continue to trend higher than their international cohorts, says a new Canadian government report. Read More
The FDA has approved Eli Lilly’s Cyramza to treat the most common type of lung cancer, the latest effort by the drugmaker to vastly increase uses of the oncology drug. Read More
A federal judge has ordered Actavis to keep the original version of its blockbuster Alzheimer’s therapy Namenda on the market while the court hears an ongoing antitrust lawsuit that claims the drugmaker wants to pull the older version to hinder generic competition. Read More
For the first time, a brand drugmaker has defeated a generics firm’s patent challenge through the U.S. Patent and Trademark Office’s internal review board process, which started in 2012. Read More